Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Werte in diesem Artikel
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.Collegium Pharmaceutical (COLL) is a stock many investors are watching right now. COLL is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value.Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. COLL has a P/S ratio of 1.94. This compares to its industry's average P/S of 3.63.Finally, our model also underscores that COLL has a P/CF ratio of 5.75. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 11.03. Over the past year, COLL's P/CF has been as high as 8.61 and as low as 5.26, with a median of 6.41.These are only a few of the key metrics included in Collegium Pharmaceutical's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, COLL looks like an impressive value stock at the moment.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Collegium Pharmaceutical, Inc. (COLL): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf Collegium Pharmaceutical
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Collegium Pharmaceutical
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Collegium Pharmaceutical Inc
Analysen zu Collegium Pharmaceutical Inc
Datum | Rating | Analyst | |
---|---|---|---|
03.05.2019 | Collegium Pharmaceutical Buy | H.C. Wainwright & Co. | |
16.01.2019 | Collegium Pharmaceutical Buy | Needham & Company, LLC | |
08.03.2018 | Collegium Pharmaceutical Buy | H.C. Wainwright & Co. | |
07.02.2018 | Collegium Pharmaceutical Buy | Needham & Company, LLC | |
05.12.2017 | Collegium Pharmaceutical Buy | Needham & Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
03.05.2019 | Collegium Pharmaceutical Buy | H.C. Wainwright & Co. | |
16.01.2019 | Collegium Pharmaceutical Buy | Needham & Company, LLC | |
08.03.2018 | Collegium Pharmaceutical Buy | H.C. Wainwright & Co. | |
07.02.2018 | Collegium Pharmaceutical Buy | Needham & Company, LLC | |
05.12.2017 | Collegium Pharmaceutical Buy | Needham & Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Collegium Pharmaceutical Inc nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen